ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Down – Here’s Why

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) gapped down prior to trading on Friday . The stock had previously closed at $90.23, but opened at $83.21. ANI Pharmaceuticals shares last traded at $93.6190, with a volume of 274,288 shares changing hands.

Analyst Upgrades and Downgrades

ANIP has been the topic of several analyst reports. Truist Financial increased their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. raised their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Buy” and a consensus price target of $99.14.

ANI Pharmaceuticals Price Performance

The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -118.88 and a beta of 0.54. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The company’s 50 day moving average is $93.64 and its 200 day moving average is $77.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. During the same quarter last year, the business posted $1.34 earnings per share. The business’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $98.04, for a total transaction of $98,040.00. Following the transaction, the senior vice president directly owned 60,186 shares in the company, valued at $5,900,635.44. This represents a 1.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Muthusamy Shanmugam sold 52,988 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the transaction, the chief operating officer directly owned 431,920 shares in the company, valued at approximately $39,062,844.80. This represents a 10.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 413,830 shares of company stock worth $36,505,378 over the last ninety days. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. Principal Financial Group Inc. boosted its position in ANI Pharmaceuticals by 68.3% in the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock valued at $10,565,000 after buying an additional 64,021 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of ANI Pharmaceuticals by 53.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock valued at $599,000 after buying an additional 3,112 shares during the last quarter. Invesco Ltd. increased its stake in shares of ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock worth $13,361,000 after buying an additional 2,022 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock worth $15,959,000 after acquiring an additional 2,220 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of ANI Pharmaceuticals by 22.4% in the 1st quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after purchasing an additional 3,086 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.